| abstract |
Use of an HMG-CoA reductase inhibitor and a PDE3 inhibitor to produce a pharmaceutical composition comprising effective amounts of an HMG-CoA reductase inhibitor and a PDE3 inhibitor to decrease triglycerides (TG), in which the HMG-CoA reductase 5 inhibitor agent is one or more of two medicinal agents selected from the group consisting of pravastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, rosuvastatin and pitavastatin. |